Spotlight on Urology

Credits: 0.50 CME / CNE / CPE
Evolving Treatment Paradigms in Advanced Prostate Cancer: Individualizing Treatment Strategies Based on Advancing Clinical Data—Part Two
Matthew Rettig, MD
Rush University Medical Center

Evolving Treatment Paradigms in Advanced Prostate Cancer: Individualizing Treatment Strategies Based on Advancing Clinical Data—Part Two

Start

Activity Details

Free CME/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: April 16, 2018
Expires: April 15, 2019
30 minutes to complete

Accredited By

Rush University Medical Center

Co-provided By

Target Audience

Healthcare providers who are involved in the treatment of patients with prostate cancer

Learning Objectives

After completing this program, participants should be able to:

  • Identify best practices for integrating current available treatment options for advanced prostate cancer, including immunologic therapies, new secondary hormonal agents, chemotherapy, and radiopharmaceuticals.
  • Understand the molecular and biochemical underpinnings of mCRPC.
  • Describe molecular biomarkers that predict for response to novel targeted therapies.

Activity Description

The activity agenda has been designed to help clinicians understand best practice approaches to utilizing all the current therapies in advanced prostate cancer to ensure optimal patient outcomes.

Faculty

Matthew B. Rettig, MD
Medical Oncologist
Ronald Reagan UCLA Medical Center and VA Greater Los Angeles Healthcare System
Los Angeles, CA

Dr. Rettig has disclosed having financial arrangements or affiliations with the following commercial interest(s) whose products or services may be mentioned in this activity:
Research Grant: Novartis
Member, Speakers Bureau: Janssen
Consultant: Janssen


Michaela Ryan, PhD
Has disclosed having no financial arrangements or affiliations with any commercial interests whose products or services may be mentioned in this activity.

Kimberly Lynch
Has disclosed having no financial arrangements or affiliations with any commercial interests whose products or services may be mentioned in this activity.

Beth-Anne M. Christopher MS, RN, CNL
Has disclosed having no financial arrangements or affiliations with any commercial interests whose products or services may be mentioned in this activity.

Conflict of Interest Policy/Disclosure Statement

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of 0.5 continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of 0.5 continuing education unit(s) in Pharmacy. UAN: JA0000275-0000-18-057-H01-P.

Instructions for Receiving Credit

Participants must complete and submit the online CE evaluation form at the conclusion of the activity and achieve a passing score of 75% or better. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by educational grants from Astellas Scientific and Medical Affairs, Inc. and Medivation, Inc., a Pfizer company, Clovis Oncology Inc., Janssen Biotech Inc. administered by Janssen Scientific Affairs, LLC, and Tolmar Pharmaceuticals, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Rush University, PleXus Communications, and/or the commercial supporters. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Rush University, PleXus Communications and/or the commercial supporters. Rush University’s ANCC accreditation status does not imply endorsement by Rush or ANCC of any commercial products displayed in conjunction with this activity. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Contact Information for Questions about the Activity

Info@plexuscomm.com
866-607-4333

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Urology Presentations

0.50 CME / CNE / CPE
Rush University Medical Center
Evolving Treatment Paradigms in Advanced Prostate Cancer: Individualizing Treatment Strategies Based on Advancing Clinical Data—Part Two

Evolving Treatment Paradigms in Advanced Prostate Cancer: Individualizing Treatment Strategies Based on Advancing Clinical Data—Part Two

Start

Activity Details

Free CME/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: April 16, 2018
Expires: April 15, 2019
30 minutes to complete

Accredited By

Rush University Medical Center

Co-provided By

Target Audience

Healthcare providers who are involved in the treatment of patients with prostate cancer

Learning Objectives

After completing this program, participants should be able to:

  • Identify best practices for integrating current available treatment options for advanced prostate cancer, including immunologic therapies, new secondary hormonal agents, chemotherapy, and radiopharmaceuticals.
  • Understand the molecular and biochemical underpinnings of mCRPC.
  • Describe molecular biomarkers that predict for response to novel targeted therapies.

Activity Description

The activity agenda has been designed to help clinicians understand best practice approaches to utilizing all the current therapies in advanced prostate cancer to ensure optimal patient outcomes.

Faculty

Matthew B. Rettig, MD
Medical Oncologist
Ronald Reagan UCLA Medical Center and VA Greater Los Angeles Healthcare System
Los Angeles, CA

Dr. Rettig has disclosed having financial arrangements or affiliations with the following commercial interest(s) whose products or services may be mentioned in this activity:
Research Grant: Novartis
Member, Speakers Bureau: Janssen
Consultant: Janssen


Michaela Ryan, PhD
Has disclosed having no financial arrangements or affiliations with any commercial interests whose products or services may be mentioned in this activity.

Kimberly Lynch
Has disclosed having no financial arrangements or affiliations with any commercial interests whose products or services may be mentioned in this activity.

Beth-Anne M. Christopher MS, RN, CNL
Has disclosed having no financial arrangements or affiliations with any commercial interests whose products or services may be mentioned in this activity.

Conflict of Interest Policy/Disclosure Statement

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of 0.5 continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of 0.5 continuing education unit(s) in Pharmacy. UAN: JA0000275-0000-18-057-H01-P.

Instructions for Receiving Credit

Participants must complete and submit the online CE evaluation form at the conclusion of the activity and achieve a passing score of 75% or better. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by educational grants from Astellas Scientific and Medical Affairs, Inc. and Medivation, Inc., a Pfizer company, Clovis Oncology Inc., Janssen Biotech Inc. administered by Janssen Scientific Affairs, LLC, and Tolmar Pharmaceuticals, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Rush University, PleXus Communications, and/or the commercial supporters. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Rush University, PleXus Communications and/or the commercial supporters. Rush University’s ANCC accreditation status does not imply endorsement by Rush or ANCC of any commercial products displayed in conjunction with this activity. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Contact Information for Questions about the Activity

Info@plexuscomm.com
866-607-4333

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME / CNE / CPE
Rush University Medical Center
Evolving Treatment Paradigms in Advanced Prostate Cancer: Individualizing Treatment Strategies Based on Advancing Clinical Data—Part One

Evolving Treatment Paradigms in Advanced Prostate Cancer: Individualizing Treatment Strategies Based on Advancing Clinical Data—Part One

Start

Activity Details

Free CME/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: April 16, 2018
Expires: April 15, 2019
30 minutes to complete

Accredited By

Rush University Medical Center

Co-provided By

Target Audience

Healthcare providers who are involved in the treatment of patients with prostate cancer

Learning Objectives

After completing this program, participants should be able to:

  • Identify best practices for integrating current available treatment options for advanced prostate cancer, including immunologic therapies, new secondary hormonal agents, chemotherapy, and radiopharmaceuticals.
  • Understand the molecular and biochemical underpinnings of mCRPC.
  • Describe molecular biomarkers that predict for response to novel targeted therapies.

Activity Description

The activity agenda has been designed to help clinicians understand best practice approaches to utilizing all the current therapies in advanced prostate cancer to ensure optimal patient outcomes.

Faculty

Matthew B. Rettig, MD
Medical Oncologist
Ronald Reagan UCLA Medical Center and VA Greater Los Angeles Healthcare System
Los Angeles, CA

Dr. Rettig has disclosed having financial arrangements or affiliations with the following commercial interest(s) whose products or services may be mentioned in this activity:
Research Grant: Novartis
Member, Speakers Bureau: Janssen
Consultant: Janssen


Michaela Ryan, PhD
Has disclosed having no financial arrangements or affiliations with any commercial interests whose products or services may be mentioned in this activity.

Kimberly Lynch
Has disclosed having no financial arrangements or affiliations with any commercial interests whose products or services may be mentioned in this activity.

Beth-Anne M. Christopher MS, RN, CNL
Has disclosed having no financial arrangements or affiliations with any commercial interests whose products or services may be mentioned in this activity.

Conflict of Interest Policy/Disclosure Statement

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of 0.5 continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of 0.5 continuing education unit(s) in Pharmacy. UAN: JA0000275-0000-18-053-H01-P.

Instructions for Receiving Credit

Participants must complete and submit the online CE evaluation form at the conclusion of the activity and achieve a passing score of 75% or better. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by educational grants from Astellas Scientific and Medical Affairs, Inc. and Medivation, Inc., a Pfizer company, Clovis Oncology Inc., Janssen Biotech Inc. administered by Janssen Scientific Affairs, LLC, and Tolmar Pharmaceuticals, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Rush University, PleXus Communications, and/or the commercial supporters. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Rush University, PleXus Communications and/or the commercial supporters. Rush University’s ANCC accreditation status does not imply endorsement by Rush or ANCC of any commercial products displayed in conjunction with this activity. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Contact Information for Questions about the Activity

Info@plexuscomm.com
866-607-4333

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.